Process Development on a Schistosomiasis Vaccine, SchistoShield???

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$600,000.00
Award Year:
2013
Program:
SBIR
Phase:
Phase I
Contract:
1R43AI103983-01
Award Id:
n/a
Agency Tracking Number:
R43AI103983
Solicitation Year:
2013
Solicitation Topic Code:
NIAID
Solicitation Number:
PA10-123
Small Business Information
PAI Life Sciences Inc., 1616 Eastlake Ave E Ste 550, SEATTLE, WA, 98102-
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
148051621
Principal Investigator:
DARRICKCARTER
(206) 623-0331
darrick.carter@proteinai.com
Business Contact:
DARRICKCARTER
(206) 623-0331
darrick.carter@proteinai.com
Research Institute:
Stub




Abstract
DESCRIPTION (provided by applicant): Schistosomiasis is a major neglected tropical disease of public health concern to a billion people with 200 million currently infected and 779 million at risk to acquire the infection, the majority of these in Africa.The disease has a high impact on affected people's lives with disability adjusted life years at 70 million years which rank this malady ahead of malaria. Current control strategies have been geared toward repeated with a drug discovered in the 1970s and standards for monitoring administration and progress have been inconsistent and inadequate. Reliance on the drug therapy approach alone is a poor strategy since this approach has had little impact on the reduction of disease transmission and there is alwaysthe inherent threat of drug resistance being developed by the parasite. A prophylactic schistosomiasis vaccine that provides at least 50% protection would play an important role in dramatically reducing the impact of this disease. Vaccine-generated immuneresponses could lead to reduced worm burdens and lower egg production and ultimately result in lower transmission. This application is an extension of our systematic and methodical approach towards developing a vaccine for schistosomiasis. Over the last twenty years, we have applied this strategy towards developing Sm-p80 into a viable vaccine candidate. At present, to our knowledge, Sm- p80 is the sole schistosome vaccine candidate that has been tested for prevention, interruption of transmission and in therapy. Our candidate vaccine has three protective effects: worm reduction, egg reduction, and protection against acute disease. Funding this application will help our continuing efforts to develop Sm-p80 towards manufacture for future human clinical trials, ultimately resulting in an approved vaccine. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: A low-cost, effective vaccine for schistosomiasis would greatly aid in the fight against this debilitating disease. By discovering and validating a new candidate vaccine we intend to progress toward a commercial product leading to an improvement in global health.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government